Brief: Evaxion Publishes Data Showing 67% Objective Response Rate In Metastatic Melanoma For AI-Designed Personalized Cancer Vaccine

Evaxion A/S

17/06/2024 13:48

June 17 (Reuters) - Evaxion Biotech A/S  EVAX.O :
    * EVAXION PUBLISHES DATA, SHOWING 67% OBJECTIVE RESPONSE
RATE IN
METASTATIC MELANOMA FOR THE AI-DESIGNED PERSONALIZED CANCER
VACCINE EVX-01, IN LEADING MEDICAL JOURNAL
    * EVAXION BIOTECH A/S: ONE-YEAR CLINICAL EFFICACY READOUT
FROM
PHASE 2 STUDY IS ON TRACK FOR Q3 2024

Source text for Eikon:  ID:nGNX3h86Xm 
Further company coverage:  EVAX.O 

 ((Reuters.Briefs@thomsonreuters.com;))